title: p27kip1 expression is inversely related to the grade of gastric MALT lymphoma.
abstract: BACKGROUND
  Decreased or lost expression of the cyclin-dependent kinase inhibitor p27kip1 protein has been found to be a poor prognostic factor in many cancers, including gastric cancer.
  
  
  OBJECTIVE
  To evaluate p27kip1 expression in gastric mucosa-associated lymphoid tissue (MALT) and gastric B-cell lymphoma.
  
  
  METHODS
  Fifty-two cases of gastric lymphoma, mean age 68.7 yr (range 23-90 yr), 11 of chronic Helicobacter pylori-associated gastritis, and 5 of normal gastric mucosa were studied. Patients were classified into two groups. Stage IE gastric lymphomas were defined as local gastric lymphoma of MALT and more advanced stages as advanced gastric lymphoma. Twenty-three patients diagnosed as stage IE, 13 of these were low-grade and 10 diffuse large B-cell lymphoma (DLBL). Twenty-nine patients were at stage IIE or above, 18 with low-grade and 11 with DLBL. Serial sections were evaluated by immunohistochemistry after staining with antibodies against p27/Kip1 and Ki-67.
  
  
  RESULTS
  The proliferative index was higher in gastric DLBL than in low-grade MALT lymphomas, 57.1+/-31.2 vs 17.3+/-20.6 (p=0.0001). The mean p27kip1 expression score for high-grade patients was significantly lower compared with that of low-grade patients, 0.5+/-0.4 and 1.6+/-0.8, respectively (p=0.001). Comparative evaluation of p27kip1 expression in malignant lymphoid cells revealed that B cells of the localized gastric DLBL patients expressed the least p27kip1, 0.36+/-0.32. This value was lower than that of malignant lymphoid cells of patients with advanced DLBL, 0.64+/-0.53, advanced low-grade MALT lymphoma, 1.59+/-0.79, and localized low-grade MALT lymphoma, 1.59+/-0.84. In the multivariate model in which all p27kip1 variables were entered, the expression of p27kip1 in malignant lymphoid cells was inversely correlated with the grade of the lymphoma irrespective of the stage of the disease (p=0.0001), and significantly predicted grade: OR:0.07, 95% CI 0.07-0.31, p=0.0001.
  
  
  CONCLUSIONS
  p27kip1 may be a putative distinct molecular marker to differentiate between low-grade and high-grade gastric lymphoma.
authors.affiliation: Department of Gastroenterology, The E. Wolfson Medical Center, Holon and Tel-Aviv University, Israel. shirin@wolf-son.health.gov.il
authors.forename: Haim
authors.initials: H
authors.lastname: Shirin
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kravtsov
authors.forename: Mark
authors.initials: M
authors.lastname: Shahmurov
authors.forename: Paulina
authors.initials: P
authors.lastname: Petchenko
authors.forename: Mona
authors.initials: M
authors.lastname: Boaz
authors.forename: Steven F
authors.initials: SF
authors.lastname: Moss
authors.forename: Yona
authors.initials: Y
authors.lastname: Avni
authors.forename: Ilana
authors.initials: I
authors.lastname: Avinoach
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000096:biosynthesis*; D050760:Cyclin-Dependent Kinase Inhibitor p27; D005260:Female; D005756:Gastritis / Q000382:microbiology; D020869:Gene Expression Profiling; D016147:Genes, Tumor Suppressor; D016481:Helicobacter Infections / Q000150:complications; D006801:Humans; D007150:Immunohistochemistry; D018442:Lymphoma, B-Cell, Marginal Zone / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D013274:Stomach Neoplasms / Q000235:genetics* / Q000473:pathology*; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*
chemical_list: D018797:Cell Cycle Proteins; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27
references.citation: Gene. 2000 Apr 18;247(1-2):1-15
references.pmid: 10773440
references.citation: Gastroenterology. 2002 May;122(5):1286-94
references.pmid: 11984515
references.citation: Blood. 1999 Jul 15;94(2):765-72
references.pmid: 10397744
references.citation: Blood. 1998 Aug 1;92(3):770-7
references.pmid: 9680343
references.citation: Am J Pathol. 1997 Jul;151(1):151-60
references.pmid: 9212741
references.citation: Cancer Res. 1989 Feb 15;49(4):1052-6
references.pmid: 2643460
references.citation: Annu Rev Med. 1999;50:401-23
references.pmid: 10073286
references.citation: Blood. 2000 Jan 15;95(2):619-26
references.pmid: 10627471
references.citation: Cancer. 1999 Apr 15;85(8):1711-8
references.pmid: 10223564
references.citation: Aliment Pharmacol Ther. 2001 Sep;15(9):1505-11
references.pmid: 11552926
references.citation: Br J Cancer. 1999 Jul;80(9):1427-34
references.pmid: 10424746
references.citation: Forum (Genova). 1998 Apr-Jun;8(2):162-73
references.pmid: 9666052
references.citation: Anticancer Res. 1998 Jul-Aug;18(4A):2403-8
references.pmid: 9703886
references.citation: Hum Pathol. 1987 Nov;18(11):1155-9
references.pmid: 3679189
references.citation: Blood. 1995 Sep 1;86(5):1924-30
references.pmid: 7655021
references.citation: Cancer. 2000 May 15;88(10):2210-9
references.pmid: 10820341
references.citation: Int J Cancer. 2001 Nov;94(4):599-604
references.pmid: 11745451
references.citation: Blood. 2003 Feb 15;101(4):1220-35
references.pmid: 12393483
references.citation: Cancer Res. 2003 Aug 1;63(15):4739-46
references.pmid: 12907657
references.citation: Ann Oncol. 1999 Jun;10(6):637-45
references.pmid: 10442184
references.citation: Hematol J. 2000;1(1):53-66
references.pmid: 11920170
references.citation: Oncogene. 1995 Jul 20;11(2):211-9
references.pmid: 7624138
references.citation: N Engl J Med. 1994 May 5;330(18):1267-71
references.pmid: 8145781
references.citation: Cancer Res. 1998 Apr 15;58(8):1730-5
references.pmid: 9563491
references.citation: Lancet. 1993 Sep 4;342(8871):575-7
references.pmid: 8102719
references.citation: Cancer Res. 1999 May 15;59(10):2277-81
references.pmid: 10344728
references.citation: Hum Pathol. 2001 Aug;32(8):769-70
references.pmid: 11521217
references.citation: Mod Pathol. 2000 Sep;13(9):1014-9
references.pmid: 11007042
references.citation: Nature. 1998 Nov 12;396(6707):177-80
references.pmid: 9823898
references.citation: Jpn J Cancer Res. 1999 Nov;90(11):1262-9
references.pmid: 10622539
references.citation: Infect Immun. 2000 Sep;68(9):5321-8
references.pmid: 10948161
references.citation: Cancer Res. 1998 Jan 1;58(1):114-22
references.pmid: 9426067
references.citation: J Gastroenterol. 2002 Jan;37(1):17-22
references.pmid: 11824795
references.citation: Cancer. 1984 Jun 1;53(11):2515-24
references.pmid: 6424928
references.citation: Cell Mol Life Sci. 2001 Nov;58(12-13):1907-22
references.pmid: 11766887
references.citation: Am J Pathol. 1999 Feb;154(2):313-23
references.pmid: 10027389